Lynx Investment Advisory Crispr Therapeutics Ag Transaction History
Lynx Investment Advisory
- $135 Billion
- Q2 2024
A detailed history of Lynx Investment Advisory transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Lynx Investment Advisory holds 125 shares of CRSP stock, worth $6,232. This represents 0.01% of its overall portfolio holdings.
Number of Shares
125Holding current value
$6,232% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
523Shares Held
58MCall Options Held
1.73MPut Options Held
1.84M-
Capital International Investors Los Angeles, CA7.87MShares$392 Million0.09% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.78MShares$388 Million3.82% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.15MShares$157 Million0.13% of portfolio
-
Nikko Asset Management Americas, Inc.3.15MShares$157 Million1.99% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$139 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.89B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....